---
layout: default
title: Iodixanol
description: "Iodixanol çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 90
evidence_level: L5
indication_count: 3
---

# Iodixanol

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Iodixanolï¼šå¾ Xå…‰å°æ¯”åŠ‘ åˆ° éª¨é—œç¯€ç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Iodixanol å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Iodixanolï¼ˆæ˜“æ¸ æ´¾å…‹ï¼‰æ˜¯ä¸€ç¨®ç­‰æ»²é€å£“çš„ç¢˜åŒ–Xå…‰å°æ¯”åŠ‘ï¼Œç”¨æ–¼å¿ƒè¡€ç®¡ã€è…¦è¡€ç®¡åŠæ³Œå°¿é“é€ å½±ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**éª¨é—œç¯€ç‚ (osteoarthritis)** æœ‰æ½›åœ¨é—œè¯ï¼Œç›®å‰æœ‰ **7 ç¯‡æ–‡ç»**æ¢è¨ç›¸é—œæ©Ÿåˆ¶ï¼Œä½†ç„¡è‡¨åºŠè©¦é©—æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | Xå…‰å°æ¯”åŠ‘ï¼šå¿ƒè‡Ÿè¡€ç®¡ã€è…¦è¡€ç®¡ã€å‘¨é‚Šå‹•è„ˆé€ å½±ç­‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | osteoarthritis susceptibilityã€osteoarthritisã€rheumatoid arthritis |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.07% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 4 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. osteoarthritis susceptibility</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.16%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Iodixanol æ˜¯ä¸€ç¨®éé›¢å­å‹ç­‰æ»²é€å£“çš„ç¢˜åŒ–å°æ¯”åŠ‘ï¼Œä¸»è¦ç”¨æ–¼å½±åƒå­¸æª¢æŸ¥ã€‚ç›®å‰ç¼ºä¹ç›´æ¥çš„è—¥ç†æ©Ÿè½‰è³‡æ–™èªªæ˜å…¶å°éª¨é—œç¯€ç‚çš„æ²»ç™‚æ½›åŠ›ã€‚

ç„¶è€Œï¼Œå¾æ–‡ç»è­‰æ“šä¾†çœ‹ï¼ŒIodixanol ä½œç‚ºé¡¯å½±åŠ‘è¢«ç”¨æ–¼é—œç¯€è»Ÿéª¨çš„ CT é€ å½±ç ”ç©¶ã€‚å¤šç¯‡ç ”ç©¶ä½¿ç”¨å°æ¯”å¢å¼·é›»è…¦æ–·å±¤ï¼ˆCECTï¼‰æŠ€è¡“çµåˆ iodixanol ä¾†è©•ä¼°è»Ÿéª¨çµæ§‹å’Œæˆåˆ†è®ŠåŒ–ï¼Œé€™äº›è®ŠåŒ–èˆ‡æ—©æœŸéª¨é—œç¯€ç‚ç›¸é—œã€‚é€™ç¨®æ‡‰ç”¨ä¸»è¦æ˜¯è¨ºæ–·æ€§è³ªï¼Œè€Œéæ²»ç™‚æ€§è³ªã€‚

TxGNN çš„é æ¸¬å¯èƒ½åæ˜ äº†è—¥ç‰©èˆ‡ç–¾ç—…åœ¨çŸ¥è­˜åœ–è­œä¸­çš„å…±ç¾é—œä¿‚ï¼ˆå¦‚æ–‡ç»ä¸­åŒæ™‚æåŠï¼‰ï¼Œè€Œéç›´æ¥çš„æ²»ç™‚æ•ˆæœã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [40155520](https://pubmed.ncbi.nlm.nih.gov/40155520/) | 2025 | Journal Article | Ann Biomed Eng | ä½¿ç”¨å…‰å­è¨ˆæ•¸CTçµåˆé›™å°æ¯”åŠ‘è©•ä¼°é—œç¯€è»Ÿéª¨å¥åº· |
| [28063646](https://pubmed.ncbi.nlm.nih.gov/28063646/) | 2017 | Journal Article | J Biomech | ä½¿ç”¨iodixanolç ”ç©¶éª¨è»Ÿéª¨ç•Œé¢çš„æº¶è³ªå‚³è¼¸ |
| [30145230](https://pubmed.ncbi.nlm.nih.gov/30145230/) | 2018 | Journal Article | Osteoarthr Cartil | ç ”ç©¶é¦¬ä¸‹é¡é«è»Ÿéª¨è€åŒ–ä¸å½±éŸ¿å£“ç¸®å‰›æ€§ |
| [39012563](https://pubmed.ncbi.nlm.nih.gov/39012563/) | 2024 | Journal Article | Ann Biomed Eng | é€éå¥ˆç±³ç²’å­æ“´æ•£æˆåƒæ­ç¤ºè»Ÿéª¨åŠŸèƒ½ |
| [27793406](https://pubmed.ncbi.nlm.nih.gov/27793406/) | 2016 | Journal Article | J Biomech | éª¨è»Ÿéª¨ç•Œé¢ä¸­æ€§æº¶è³ªå‚³è¼¸çš„æœ‰é™å…ƒåˆ†æ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. osteoarthritis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.07%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.07%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. rheumatoid arthritis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.00%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.00%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›ç½²è—¥è¼¸å­—ç¬¬023365è™Ÿ | æ˜“æ¸ æ´¾å…‹ æ³¨å°„åŠ‘ 270å…¬çµ²ç¢˜/å…¬æ’® | æ³¨å°„åŠ‘ | Xå…‰å°æ¯”åŠ‘ï¼šç”¨æ–¼å¿ƒè‡Ÿè¡€ç®¡ã€è…¦è¡€ç®¡ã€å‘¨é‚Šå‹•è„ˆé€ å½±... |
| è¡›ç½²è—¥è¼¸å­—ç¬¬023367è™Ÿ | æ˜“æ¸ æ´¾å…‹ æ³¨å°„åŠ‘ 320æ¯«å…‹ç¢˜/æ¯«å‡ | æ³¨å°„åŠ‘ | Xå…‰å°æ¯”åŠ‘ï¼šç”¨æ–¼å¿ƒè‡Ÿè¡€ç®¡ã€è…¦è¡€ç®¡ã€å‘¨é‚Šå‹•è„ˆé€ å½±... |

## å®‰å…¨æ€§è€ƒé‡

**è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š

ä¸»è¦äº¤äº’ä½œç”¨ï¼ˆMajorï¼‰ï¼š
- Metforminï¼šå¯èƒ½å¢åŠ ä¹³é…¸é…¸ä¸­æ¯’é¢¨éšª
- Amphotericin Bï¼šå¯èƒ½å¢åŠ è…æ¯’æ€§
- Vancomycinã€Aminoglycosidesï¼ˆAmikacin, Gentamicin, Kanamycinï¼‰ï¼šå¯èƒ½å¢åŠ è…æ¯’æ€§
- Cyclosporineã€Tacrolimusï¼šå¯èƒ½å¢åŠ è…æ¯’æ€§
- NSAIDsï¼ˆKetorolac, Ibuprofen, Naproxen, Celecoxibï¼‰ï¼šå¯èƒ½å¢åŠ è…æ¯’æ€§
- Cisplatinï¼šå¯èƒ½å¢åŠ è…æ¯’æ€§

ä¸­åº¦äº¤äº’ä½œç”¨ï¼ˆModerateï¼‰ï¼š
- Beta-blockersï¼ˆMetoprolol, Atenolol ç­‰ï¼‰
- åˆ©å°¿åŠ‘ï¼ˆFurosemide, Hydrochlorothiazide ç­‰ï¼‰


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Anemia, Sickle Cell** ğŸŸ¡ Moderate
- Some contrast agents have shown to promote the phenomenon of sickling (blood cell rupture) in individuals who are homozygous for sickle cell disease when administered intravenously or intra- arterially.  Caution is advised.

**Multiple Myeloma** ğŸŸ¡ Moderate
- A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma.  In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death.  Although neither the con...

**é‡ç—‡è‚Œç„¡åŠ› (Myasthenia Gravis)** ğŸŸ¡ Moderate
- The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis.  Caution is advised when using these agents in patients with this condition.

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- In patients with advanced renal disease, iodinated contrast media should be used with caution, and only when the need for the examination dictates, since the excretion of the medium may be impaired.  Patients with combined renal and hepatic disease, ...

**Hypersensitivity** ğŸŸ¡ Moderate
- Iodixanol can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis.  Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock.  Most severe reactions develop shortly after the start of t...

*å¦æœ‰ 2 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
æ–‡ç»ä¸­ iodixanol èˆ‡éª¨é—œç¯€ç‚çš„é—œè¯ä¸»è¦ä¾†è‡ªè¨ºæ–·æ€§æ‡‰ç”¨ï¼ˆé¡¯å½±åŠ‘ç”¨æ–¼è»Ÿéª¨é€ å½±ï¼‰ï¼Œè€Œéæ²»ç™‚æ•ˆæœã€‚ç¼ºä¹æ©Ÿè½‰æ”¯æŒå’Œè‡¨åºŠè©¦é©—è­‰æ“šè¡¨æ˜é€™å€‹é æ¸¬å¯èƒ½æ˜¯çŸ¥è­˜åœ–è­œä¸­çš„å½ç›¸é—œã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ˜ç¢ºçš„è—¥ç†æ©Ÿè½‰ç ”ç©¶æ”¯æŒæ²»ç™‚æ½›åŠ›
- é«”å¤–/é«”å…§å¯¦é©—é©—è­‰ iodixanol å°è»Ÿéª¨çš„ç›´æ¥æ•ˆæœ
- ç›®å‰ä¸å»ºè­°é€²ä¸€æ­¥æ¢ç´¢æ­¤é©æ‡‰ç—‡


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Deoxycholic Acid]({{ "/drugs/deoxycholic_acid/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Brivaracetam]({{ "/drugs/brivaracetam/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Sacituzumab Govitecan]({{ "/drugs/sacituzumab_govitecan/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Dipyridamole]({{ "/drugs/dipyridamole/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Oxytetracycline]({{ "/drugs/oxytetracycline/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Iodixanolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/iodixanol/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_iodixanol,
  title = {Iodixanolè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/iodixanol/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
